pdufa.bio

IZERVAY (avacincaptad pegol intravitreal solution)

Updated ยทnext FDA decision on the calendar

IZERVAY (avacincaptad pegol intravitreal solution) 1 FDA decision on record below. Every date links its source.

ALPMY catalyst hub

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

PDUFA · Feb 13, 2025 ✓ ApprovedALPMY

Questions

When is IZERVAY (avacincaptad pegol intravitreal solution)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for IZERVAY (avacincaptad pegol intravitreal solution); 1 FDA decision is on record below.

What happened at IZERVAY (avacincaptad pegol intravitreal solution)'s most recent FDA decision?

On Feb 13, 2025 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has IZERVAY (avacincaptad pegol intravitreal solution) been approved by the FDA?

Yes. The FDA approved an application for IZERVAY (avacincaptad pegol intravitreal solution) on Feb 13, 2025; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.